Replies to post #242702 on Biotech Values

[jbog]

Yes I have a position but sadly it's still about a buck below my cost average.

We'll see what happens

[DewDiligence]

AMRN…[has] been a good trade since Dew noted how low its EV value got about a month ago.

Glad to be of service, LOL.

By the way, I thought the prevailing view among people who post about AMRN on iHub was that Sarissa could accomplish more for ordinary AMRN shareholders by not having seats on the BoD and thereby being free to take actions seen as hostile to the BoD.

[spongepaul]

We asked my wife’s GP for vascepa when her triglycerides were regularly elevated (middle age, not overweight, good health otherwise). Her triglyceride level improved immensely and anecdotally, she felt like a million bucks on regular dose.
Before the patent trial finished, vascepa was on her insurance provider’s “preventative maintenance”drug list and our copay was small - all total a few dollars per month. Ironically, when the reduce-it results became well known, they took it off the list and it went to well over $300/mo. Out of pocket.